Aclarion, Inc. (ACON) vs Aprea Therapeutics, Inc. (APRE)
A side-by-side comparison of Aclarion, Inc. and Aprea Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACON
Aclarion, Inc.
$2.34HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
APRE
Aprea Therapeutics, Inc.
$0.68HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ACON vs APRE
growth of $100 · dividends reinvested · last 4yACON -100.0% (-95.1%/yr)APRE -97.7% (-61.2%/yr)APRE compounded faster over this window
Log scale — wide-divergence pair
ACON APRE
ACON vs APRE: by the numbers
- •APRE is the larger company ($8M vs $7M market cap).
- •Both run net losses; APRE's is the smaller (0.00% vs -10978.48% net margin).
Metrics side by side
Valuation
| Metric | ACON | APRE |
|---|---|---|
| P/S ratio | 80.52 | N/A |
| P/B ratio | 0.40 | 0.22 |
Profitability
| Metric | ACON | APRE |
|---|---|---|
| Gross margin | -291.27% | 0.00% |
| Operating margin | -9312.55% | 0.00% |
| Net margin | -10978.48% | 0.00% |
| ROE | -54.09% | -31.99% |
| ROIC | -57.11% | -33.73% |
Growth (annualized)
| Metric | ACON | APRE |
|---|---|---|
| Revenue CAGR (5Y) | 3.75% | N/A |
| Total return CAGR (5Y) | N/A | -63.30% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.